Eli Lilly (LLY) Stock Dips on Foundayo Liver Safety Concerns: Should You Buy?

Table of Contents Shares of Eli Lilly experienced a roughly 3% decline Monday morning following comments from Evercore ISI analyst Umer Raffat, who highlighted a hepatic failure incident in the FDA Adverse Event Reporting System (FAERS) associated with Foundayo, the pharmaceutical giant’s recently introduced oral GLP-1 medication. Eli Lilly and Company, LLY The reported incident involved a 56-year-old man and potentially took place on or prior to April 15. The documentation was filed with the FDA on April 30. LLY traded around $934 during early Monday sessions before staging a partial rebound. Meanwhile, competitor Novo Nordisk (NVO) gained approximately 2% following the disclosure. Raffat emphasized that this single case shouldn’t be examined without context. He observed that hepatic failure incidents have been documented across various GLP-1 medications — with Ozempic showing 33 reported instances, Wegovy showing 15, Mounjaro showing 30, and Zepbound showing 2. He stated that the “onus is on LLY” to guarantee thorough and rapid evaluation of liver-related cases to prevent misunderstanding, particularly considering previous hepatic toxicity questions surrounding other oral GLP-1 compounds, including one developed by Pfizer. Lilly responded promptly to the matter. The pharmaceutical company rejected the report after concluding it had no connection to Foundayo. Wolfe analyst Alexandria Hammond supported Lilly’s assessment. She characterized the pre-market response as “overdone” and indicated she would pursue buying opportunities during the weakness. Bernstein’s Christian Moore concurred. He argued it was improbable that a liver toxicity signal went undetected considering the substantial clinical trial data compiled for Foundayo, and similarly stated he was purchasing shares during the dip. Foundayo’s hepatic profile underwent evaluation in numerous studies, including the 2,800-participant ACHIEVE-4 trial, which examined hepatic safety at the FDA’s directive and identified no safety concerns. Since debuting last month, Foundayo has already attracted 20,000 patients. An important factor: 80% of these individuals are entirely new to GLP-1 therapies, indicating the oral formulation is broadening the addressable market instead of stealing share from injectable products. Foundayo possesses a convenience advantage compared to Novo Nordisk’s oral Wegovy — it doesn’t mandate an empty stomach, simplifying integration into patients’ everyday schedules. Lilly is simultaneously making headway in expanding provider awareness and securing placement in major pharmacy networks. The stock decline occurred despite Lilly delivering impressive quarterly performance last week. Mounjaro revenue surged 125% to $8.6 billion while Zepbound increased 80% to $4.1 billion. Lilly commands approximately 60% of the U.S. market share within the GLP-1 drug category, supported partially by head-to-head clinical trial results demonstrating superior weight reduction compared to rival medications. The pharmaceutical company continues advancing additional weight management candidates throughout its development pipeline.